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abstract: The etiology of preeclampsia is complex, with susceptibility being attributable to multiple environmental factors and a large
genetic component. Although many candidate genes for preeclampsia have been suggested and studied, the speciﬁc causative genes still
remain to be identiﬁed. Catechol-O-methyltransferase (COMT) is an enzyme involved in catecholamine and estrogen degradation and
has recently been ascribed a role in development of preeclampsia. In the present study, we have examined the COMT gene by genotyping
the functional Val108/158Met polymorphism (rs4680) and an additional single-nucleotide polymorphism, rs6269, predicting COMT activity
haplotypes in a large Norwegian case/control cohort (ncases¼ 1135, ncontrols¼ 2262). A low COMT activity haplotype is associated with
recurrent preeclampsia in our cohort. This may support the role of redox-regulated signaling and oxidative stress in preeclampsia pathogen-
esis as suggested by recent studies in a genetic mouse model. The COMT gene might be a genetic risk factor shared between preeclampsia
and cardiovascular diseases.
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Introduction
The pregnancy-associated complication preeclampsia is a leading cause
of maternal and fetal morbidity and mortality. Approximately 3% of all
pregnant women in populations of European descent are affected by
preeclampsia (Saftlas et al., 1990). In severe cases of preeclampsia, the
only effective treatment is delivery, irrespective of gestational age. The
classical clinical manifestations of preeclampsia are elevated blood
pressure and proteinuria. The etiology is complex and like in other
common complex disorders both genetic and environmental factors
inﬂuence the risk of developing the disease. Genetic factors are
suggested to be responsible for .50% of the liability to preeclampsia
(Salonen Ros et al., 2000; Moses et al., 2006), and several candidate
genes have been studied. However, the results are inconsistent and
speciﬁc causative genes involved in preeclampsia still remain to
be identiﬁed (Broughton Pipkin, 1999; Roberts and Cooper, 2001;
Consortium, 2005; Chappell and Morgan, 2006; Mutze et al., 2008;
Nejatizadeh et al., 2008).
A recent animal study put forward the suggestion that deﬁciency in
catechol-O-methyltransferase (COMT) is associated with preeclamp-
sia (Kanasaki et al., 2008). COMT is a key enzyme in the degradation
of both catecholamines and estrogens (Creveling, 2003). High- and
low-activity variants of COMT, due to single base changes, have
been discovered (Diatchenko et al., 2005). One polymorphism with
functional implications is a non-synonymous G to A base change
(rs4680; NM_000754.2), the COMT Val108/158Met polymorphism.
This polymorphism results in a substitution of the amino acid valine
for methionine at codon 108 and 158 in the soluble and membrane
bound isoforms of COMT, respectively. The Met(A)-allele of this poly-
morphism is associated with a 3- to 4-fold decrease in COMT enzyme
activity (Lotta et al., 1995), and several clinical conditions such as pain
perception (Zubieta et al., 2003; Diatchenko et al., 2005), psychiatric
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2008), hypertension (Happonen et al., 2006; Hagen et al., 2007a, b;
Annerbrink et al., 2008) and heart disease (Eriksson et al., 2004;
Hagen et al., 2007a, b; Voutilainen et al., 2007) have been reported
to be associated with this base change.
Inspired by Kanasaki et al.’s hypothesis that COMT deﬁciency is
associated with preeclampsia, we examined the potential role of
high and low activity haplotypes in the central region of COMT. The
functional COMT Val108/158Met polymorphism and an additional
single-nucleotide polymorphism (SNP; rs6269) were genotyped to
account for the three major haplotypes observed in the central
region of COMT in populations of European descent (Gabriel et al.,
2002; Diatchenko et al., 2005).
Materials and Methods
The HUNT population
All women subjected to genotyping were retrospectively identiﬁed from
the second Nord-Trøndelag Health Study (HUNT2) (Holmen et al.,
2003). Preeclampsia was deﬁned as the onset of persistent hypertension
(exceeding 140/90 mmHg), in combination with proteinuria (exceeding
300 mg/l per day) after 20 weeks gestation. Women with preeclamptic
(cases) and non-preeclamptic (controls) singleton pregnancies in the
HUNT2 cohort were identiﬁed by linking the HUNT database to the
Medical Birth Registry of Norway (MBRN) (Moses et al., 2008). The
inhabitants of Nord-Trøndelag county are well suited for genetic studies
due to ethnic homogeneity (,3% non-Caucasians) (Holmen et al.,
2003, 2004). The HUNT2 preeclampsia cohort is described in detail else-
where (Moses et al., 2008; Fenstad et al., 2010).
Clinical characterization of the HUNT2 preeclampsia cohort
Cases registered with one preeclamptic pregnancy were deﬁned as non-
recurrent, and cases with more than one preeclamptic pregnancy were
deﬁned as recurrent. The non-recurrent preeclampsia group also included
women with only one registered pregnancy in the MBRN. Preterm delivery
was deﬁned as delivery before 37 weeks (Gifford et al., 2000). Small for
gestational age (SGA) was deﬁned as an infant with a birthweight ≤2 stan-
dard deviations (SDs) below the expected weight for gestational age and
sex, corresponding to the 2.5 percentile (Marsal et al., 1996). For assess-
ment of metabolic syndrome, an International Diabetes Federation (IDF)
proxy deﬁnition [waist circumference ≥80 cm plus any two of high
density lipid (HDL) cholesterol ,1.29, treatment for hypertension or
blood pressure ≥130/≥85 mm Hg, diabetes diagnosed after age of 30]
(Hildrum et al., 2007) was used, as fasting blood glucose was not available
for all the individuals in the study cohort. Using the IDF proxy deﬁnition in
a cross-sectional analysis of 10 206 HUNT2 participants, Hildrum et al.
showed that there was no differences in the prevalence of metabolic syn-
drome between fasting and non-fasting groups (Hildrum et al., 2007).
SNP genotyping
DNA for genotyping was extracted from blood samples stored in the
HUNT biobank, as described elsewhere (Moses et al., 2008). Applied
Biosystems’ TaqMan genotyping assays (Applied Biosystems, Foster City,
CA, USA) were selected to genotype the rs4680 (Val108/158Met) and
rs6269 SNPs using 5 ng of genomic DNA from each of the case and
control samples. The assays were performed on an Applied Biosystems
7900HT Fast Real-Time PCR System at HUNT biobank and sample
genotypes were interrogated using the integrated 7900HT system data
analysis software. The genotyping procedure has been validated at
HUNT biobank by LightCycler (Roche Diagnostics Scandinavia AB,
Stockholm, Sweden) hybridization probe genotyping and DNA sequencing
of rs4680.
Haplotype analysis
Haplotypes werepredictedfrom genotype information fromeachindividual
using the computer program Phase (http://stephenslab.uchicago.edu/
home.html) (Stephens et al., 2001; Stephens and Donnelly, 2003). Only
individuals with both SNPs successfully genotyped were included in the
haplotype analysis (n ¼ 3036; ncontrols¼ 2029, ncases¼ 1007; nnon-recurrent¼
888, nrecurrent¼ 119). The frequency of the haplotypes was also calculated
based on this number of individuals.
Only a few common COMT haplotypes are observed in populations of
European descent (Gabriel et al., 2002; Diatchenko et al., 2005), and three
major COMT haplotypes accounting for  96% of all detected haplotypes
in the coding region determine the COMT activity in humans (Diatchenko
et al., 2005). Figure 1 shows these three major haplotypes that are demon-
strated to constitute four central SNPs (rs6269, rs4633, rs4818 and
rs4680) (Diatchenko et al., 2005). These three haplotypes are associated
with very different COMT enzyme activities (Nackley et al., 2006), and
have also been demonstrated to be associated with variation in sensitivity
to experimental pain. They were therefore designated as low pain sensi-
tivity (LPS), average pain sensitivity (APS) and high pain sensitivity (HPS)
(Diatchenko et al., 2005). There is an inverse correlation between pain
sensitivity and COMT activity, meaning that the LPS haplotype represents
the high COMT activity haplotype, whereas the HPS represents the low
COMT activity haplotype and the APS represents the intermediate
COMT activity haplotype.
In this study, the genotyped SNPs (rs4680 and rs6269) were selected
based on the observation that only two of the central four SNPs were
needed to tag the variation in a Norwegian sample set (Halleland et al.,
2009). It was observed that there is strong pair wise linkage disequilibrium
(LD) with almost perfect correlation (r
2. 0.97) between rs6269–rs4818
and rs4633–rs4680, and that the rs6269 SNP tags the high COMT activity
haplotype (Halleland et al., 2009).
Figure 1 Haplotypes in the central region of the COMT gene.
[(Figure modiﬁed from Andersen and Skorpen (2009)]. A total of
four central SNPs in the COMT gene have been demonstrated to
combine into three common haplotypes (Diatchenko et al., 2005)
which have been associated with variation in COMT enzyme activity
(Nackley et al., 2006). The two SNPs marked with a pale blue rec-
tangle, rs6269 and rs4680, in combination differentiate between the
three common activity haplotypes (Halleland et al., 2009) and were
the ones genotyped in the present study. Frequencies for the haplo-
types detected shown in this ﬁgure are consistent with previous ﬁnd-
ings and the frequencies observed by Diatchenko et al. are shown in
brackets.
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Clinical characterisation
The software package SPSS 16.0 for Windows was used to compute
descriptive statistics such as mean and SD. P-values were computed
based on t-test statistics for normally distributed variables. Non-
parametrical methods (x
2) were used for categorical variables. The non-
recurrent and recurrent preeclampsia groups were analyzed separately.
Each preeclamptic group was compared with the non-preeclamptic
group. Multivariate logistic regression was used to model preeclampsia
as the (dichotomous) dependent variable against maternal age. A
threshold of a ¼ 0.05 was set for statistical signiﬁcance of all computed
analyses.
SNP and haplotype association analysis
Concordance with Hardy–Weinberg proportions was tested using a x
2
goodness-of-ﬁt statistic. The SNP association analyses for the Val108/
158Met (rs4680) and rs6269 SNPs and haplotype association analyses
for the four possible haplotypes (Fig. 1) were carried out in PASW Stat-
istics version 17 using a Pearson’s x
2 statistic. The SNPs and haplotypes
were analyzed separately for the subgroups of preeclamptic women (non-
recurrent and recurrent) against non-preeclamptic control women. An
additive (A allele frequency versus G allele frequency) genetic model was
used for the SNP association analysis. For the haplotype association ana-
lyses, we tested whether carrying one of the four possible haplotypes
was associated with disease state. Odds ratios (ORs) with 95% conﬁdence
intervals (CIs) were calculated. A threshold of a ¼ 0.05 was set for stat-
istical signiﬁcance of all computed analyses.
Ethics
The study was approved by the Regional Committee for Medical Research
Ethics, the National Data Inspectorate and The Directorate of Health and
Social Welfare in Norway.
Results
Statistical power analysis
Using a relevant range of minor allele frequencies (30–50%) [National
Center for Biotechnology Information (NCBI) SNP database], a priori
power calculations ad modum Lalouel and Rhorwasser (Lalouel and
Rohrwasser, 2002) for the genotyped SNPs demonstrated 80%
power to detect an effect size (OR) difference of 1.25 for the non-
recurrent group (n ¼ 1003) and 1.65–1.75 for the subgroup of
women with recurrent preeclampsia (n ¼ 136).
Clinical characterization
The original HUNT2 preeclampsia cohort (1139 cases and 2269 con-
trols) was used when performing the clinical characterisation (Moses
et al.,2 0 0 8 ; Fenstad et al.,2 0 1 0 ). Mean follow-up time from index preg-
nancy recorded in MBRN to inclusion in the present study was 25+10
years. Gestational age and birthweight differed between the neonates in
preeclamptic and non-preeclamptic pregnancies, the preeclamptic
women had a higher risk of preterm delivery, and of delivering a SGA
neonate (Table I, P , 0.001). Metabolic syndrome was evaluated by
data from the HUNT2 study and was higher in the case groups when
compared with controls (Table I, P , 0.001). After adjusting for
maternal age, the differences in clinical phenotype between case and
control groups remained signiﬁcant (Table I, P , 0.001).
We also observed clinical differences between the group of women
with recurrent and non-recurrent preeclampsia (Table I). The women
with recurrent preeclampsia delivered earlier (P ¼ 0.018) and had a
higher prevalence of preterm birth (22%) compared with the
women with non-recurrent preeclampsia (16%; P , 0.01). The neo-
nates from the recurrent preeclamptic pregnancies had a lower birth-
weight (adjusted for gestational age, P ¼ 0.055), but the seemingly
different prevalence of SGA (20 versus 15% recurrent versus non-
recurrent) was not statistically signiﬁcant (P ¼ 0.2). The P-values
were adjusted for maternal age. The group of women with recurrent
preeclampsia also had a higher prevalence of metabolic syndrome
at inclusion in the HUNT2 study compared with the women
with non-recurrent preeclampsia when adjusting for age at inclusion
(P ¼ 0.019).
COMT genotyping and association analysis
DNA samples were available for 1135 women registered with pree-
clamptic pregnancies and 2262 controls. We observed a high genotyp-
ing success rate for the rs4680 and rs6269 SNPs in both cases (94%)
and controls (95%), and both SNPs conformed to Hardy–Weinberg
proportions (P . 0.05). Approximately 10% of our samples were gen-
otyped on both the TaqMan and the LightCycler genotyping system
........................................................................................
Table I Clinical characteristics of the HUNT2
preeclampsia case/control cohort.
Preeclampsia
(non-recurrent,
n 5 1003)
Preeclampsia
(recurrent
a,
n 5 136)
Control
(n 5 2269)
Maternal age
at index
pregnancy
(years)
27+6* 25+52 5 +5
Gestational
age (days)
275+22* 271+20* 282+18
Birthweight
(g)
3.238+837* 3.040+846* 3.483+592
SGA
b 147 (15)* 26 (20)* 87 (4)
Preterm
birth
c
132 (14)* 29 (22)* 114 (5)
Maternal age
atinclusionin
HUNT2
40+11 37+9* 40+11
Metabolic
syndrome
d
163 (16)* 30 (22)* 212 (9)
Data presented as mean+SD or number (percentage). P-values are computed by
comparing each preeclamptic group to the non-preeclamptic control group.
IDF, the International Diabetes Federation; HDL, high-density lipoprotein; CI,
conﬁdence interval.
aMore than one preeclamptic pregnancy.
b≤2SD of expected weight.
cDelivery before Week 37.
dIDF-proxy deﬁnition; waist circumference ≥80 cm plus any two of (HDL
cholesterol ,1.29, treatment for hypertension or blood pressure
≥130/≥85 mmHg, diabetes diagnosed after age of 30 or fasting plasma glucose
≥5.6 mmol/l) (Hildrum et al., 2007).
*P , 0.001.
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COMT SNPs and non-recurrent preeclampsia was observed in our
Norwegian cohort (Table II). However, a signiﬁcant overrepresenta-
tion of the wild type allele (Val (G)), not the low activity allele (Met
(A)), of the Val108/158Met polymorphism (rs4680) was observed in
the group of women with recurrent preeclampsia (P ¼ 0.047, OR ¼
0.77, CI 0.6–1.0) (Table II). No association was observed between
rs6269 and recurrent preeclampsia (Table II).
The three common COMT haplotypes as well as the less frequent
G-A (rs6269–rs4680) haplotype were detected in our Norwegian
cohort (Table III and Fig. 1). The frequencies of the three common
haplotypes in our cohort are shown in Fig. 1 and are consistent
with frequencies observed in other studies (Fig. 1)( Diatchenko
et al., 2005; Rakvag et al., 2008; Halleland et al., 2009). The less
frequent G–A haplotype observed in our cohort is likely to be the
G–C–C–A haplotype observed by Diatchenko et al. (Diatchenko
et al., 2005), as this is the only haplotype with G–A at the two
SNPs genotyped in the current study. We found that carrying the
low COMT activity haplotype was signiﬁcantly associated with recur-
rent preeclampsia (P ¼ 0.018, OR ¼ 1.8, CI 1.1–2.8) (Table III).
The non-recurrent preeclampsia group did not show association
with any of the haplotypes.
Discussion
Growing evidence supports the role of COMT in human pregnancy.
The COMT enzyme is reported to be active in both placenta
(Barnea et al., 1988) and decidua (Casey and MacDonald, 1983),
and expression in human fetal membranes has recently been reported
(Harirah et al., 2009). Decreased placental COMT activity was ﬁrst
...................... ....................................... ................................. .........................................................
.............................................................................................................................................................................................
Table II Distribution of COMT genotypes and alleles in the HUNT2 preeclampsia case/control cohort.
SNP Genotype (NN) Preeclampsia non-recurrent Preeclampsia recurrent Control OR CI
Allele (N) n (proportion of total) n (proportion of total) n (proportion of total)
rs4680 (Val108/
158Met)
GG 174 (0.18) 36 (0.28) 412 (0.19)
AG 461 (0.48) 60 (0.46) 1097 (0.50)
AA 335 (0.35) 35 (0.27) 678 (0.31)
A( Met) 1131 (0.58) 130 (0.50) 2453 (0.56) 1.1
a 1.0–1.2
a
G( Val) 809 (0.42) 132 (0.50) 1921 (0.44) 0.8
b,* 0.6–1.0
b
rs6269 AA 361 (0.39) 47 (0.39) 771 (0.37)
GA 412 (0.45) 52 (0.43) 1035 (0.49)
GG 143 (0.16) 23 (0.19) 289 (0.14)
A 1134 (0.62) 146 (0.60) 2577 (0.62) 1.0
a 0.9–1.1
a
G 698 (0.38) 98 (0.40) 1613 (0.39) 0.9
b 0.7–1.2
b
OR, odds ratio; CI, 95% conﬁdence interval.
aPreeclampsia non-recurrent versus control.
bPreeclampsia recurrent versus control.
*Signiﬁcantly different from the value for the control group when compared with the frequency of the G allele using Pearson’s x
2 analysis in a 2 × 2 contingency table (x
2¼ 4.185,
P ¼ 0.047).
.............................................................................................................................................................................................
Table III COMT haplotypes in the HUNT2 preeclampsia case/control cohort.
Haplotype rs6269 –rs4680
(N-N)
Preeclampsia
non-recurrent (proportion)
Preeclampsia recurrent
(proportion)
Control
(proportion)
OR CI
1 (high activity) G–G 516 (0.58) 72 (0.61) 1237 (0.61) 0.9
a 0.8–1.0
a
1.0
b 0.7–1.4
b
2 (intermediate activity) A–A 710 (0.80) 87 (0.73) 1627 (0.80) 1.0
a 0.8–1.2
a
0.7
b 0.4–1.0
b
3 (low activity) A–G 110 (0.12) 25 (0.21) 263 (0.13) 1.0
a 0.8–1.2
a
1.8
b* 1.1–2.8
b
4 (unknown activity) G–A 30 (0.03) 2 (0.02) 58 (0.03) 1.2
a 0.8–1.9
a
0.6
b 0.1–2.4
b
Proportions represent the proportion of individuals being a carrier of the haplotype tested (number of individuals carrying haplotype X divided on total number of individuals in the
studied subgroup).
OR, odds ratio; CI, 95% conﬁdence interval.
aPreeclampsia non-recurrent versus control.
bPreeclampsia recurrent versus control.
*Signiﬁcantly different from the value for the control group when compared with the frequency of the other haplotypes combined using Pearson’s x
2 analysis in a 2 × 2 contingency
table (x
2¼ 0.57, P ¼ 0.018).
442 Roten et al.reported to be associated with hypertension in pregnancy (Barnea
et al., 1988). More recently, reduced placental COMT protein
expression has been observed in women with severe preeclampsia
(Kanasaki et al., 2008). On the basis of the latter observation, together
with observations from studying COMT knockout mice, COMT was
introduced as a preeclampsia susceptibility gene (Kanasaki et al.,
2008). The Comt2/2 mice developed a preeclampsia-like syndrome,
with elevated blood pressure, albuminiuria, glomerular changes, pla-
cental thrombosis, and hypoxia and preterm birth. However, adminis-
tration of 2-methoxyestradiol (2-ME), a natural estrogen metabolite
produced by COMT, to pregnant Comt2/2 mice ameliorated the
preeclampsia-like symptoms (Kanasaki et al., 2008). It was suggested
that genetic variation within the COMT gene could be an explanation
for disruption of COMT and 2-ME in preeclamptic women (Kanasaki
et al., 2008).
SNPs in the COMT gene have been shown to signiﬁcantly affect
enzyme activity (Lotta et al., 1995; Diatchenko et al., 2005; Nackley
et al., 2009). It was therefore reasonable to hypothesize that SNPs
in this gene are associated with preeclampsia pathogenesis. Recently,
the Val108/158Met polymorphism was shown to be associated with
preeclampsia in a small Korean population cohort of 164 preeclamptic
and 182 normotensive patients (Lim et al., 2010). However, it has
become clear that the Val108/158Met polymorphism alone is not
likely to account for the variation of COMT enzyme activity. Four
central SNPs (rs6269, rs4633, rs4818 and rs4680) in the COMT
gene combine to form three common haplotypes (Diatchenko et al.,
2005), and these are associated with varying levels of COMT
enzyme activity (Nackley et al., 2006) (Fig. 1). The fact that the wild
type Val108/158 (G) allele is present in both the high and low
COMT activity haplotypes (Diatchenko et al., 2005) demonstrates
the importance of studying haplotypes rather than single SNPs. We
therefore performed haplotype analysis to see whether any of the
three common haplotypes (Fig. 1) were associated with preeclampsia.
We found that the low COMT activity haplotype, with a 58-fold
reduced enzyme activity (Nackley et al., 2009), was signiﬁcantly associ-
ated with recurrent preeclampsia (P ¼ 0.018), with an OR of 1.8 (CI
1.1–2.8) for carrying this haplotype. Consistent with other studies,
our group of women with recurrent preeclampsia showed the
highest risk of preterm labor, low fetal birthweight and the highest
risk of later life cardiovascular disease (assessed as metabolic syn-
drome) (Sibai et al., 1991; Odegard et al., 2000; Magnussen et al.,
2009). Therefore, our ﬁndings support the hypothesis that lower
maternal COMT enzyme activity predisposes to severe preeclampsia.
Angiogenesis, the formation of new blood vessels, is a central
process in development of both preeclampsia and cardiovascular dis-
eases. Alterations in angiogenesis during early pregnancy contribute to
incomplete remodeling of uterine spiral arteries and abnormal placen-
tal vascular development (Roberts and Cooper, 2001). Decreased
COMT activity and subsequent reduced levels of estrogen metab-
olites, such as 2-ME, may impair vascular health in several ways.
(LaVallee et al., 2003; Barchiesi et al., 2006; Dubey et al., 2007;
Dubey and Jackson, 2009). It has been demonstrated that 2-ME
has antiangiogenic effects (Fotsis et al., 1994), suppressing
hypoxia-inducible factor-1a (HIF-1a), which plays an essential role
in angiogenesis. This transcription factor is responsible for the induc-
tion of genes that facilitate the adaption and survival of cells during
low-oxygen levels (Wang et al., 1995; Semenza, 1998), including
soluble fms-like tyrosine kinase 1. 2-ME has recently been suggested
to be an important co-stimulator together with low-oxygen levels
for induction of the invasiveness of trophoblasts (Lee et al., 2010).
Thus, it has been suggested that 2-ME plays a role in maintaining pla-
cental homeostasis (Kanasaki and Kalluri, 2009). Disturbances in
COMT and 2-ME homeostasis and regulation may cause placental
pathology in different ways at different stages of the pregnancy. A pre-
mature increase in 2-ME has been hypothesized to disturb hypoxia-
driven trophoblast invasion and vascular remodeling and therefore
contribute to preeclampsia pathogenesis (Lee et al., 2010). In late
pregnancy, decreased COMT activity, thus lower levels of 2-ME and
decreased inhibition of HIF-1a could potentially cause vascular pathol-
ogy and inﬂammatory activation (Banerjee et al., 2009). Studies exam-
ining the expression and activity of the COMT enzyme throughout
pregnancy are warranted to clarify the role of COMT/2-ME at differ-
ent stages of the pregnancy.
Acting as a pro-oxidant, 2-ME has direct involvement in redox-
regulated signaling (Banerjee et al., 2009), a possible shared disease
mechanism between preeclampsia and cardiovascular diseases. Fur-
thermore, the COMT enzyme is also important for homocysteine
metabolism, a known cardiovascular risk factor (Shenoy et al.,
2010). A combination of high serum homocysteine levels and the
low activity Val108/158 allele conferred increased risk (hazard risk
ratio of 2.94) of acute coronary events in middle-aged men from
eastern Finland (Voutilainen et al., 2007). A similar mechanism has
been suggested for preeclampsia (Shenoy et al., 2010). Such epigenetic
effects might explain the diverging results found in both genetic studies
concerning COMT and epidemiologic studies concerning vitamin B and
homocysteine levels (Ray and Laskin, 1999; Sanchez et al., 2001; Eriks-
son et al., 2004; Mignini et al., 2005; Happonen et al., 2006; Hagen
et al., 2007a, b; Voutilainen et al., 2007; Annerbrink et al., 2008; Hint-
sanen et al., 2008; Guven et al., 2009; Nackley et al., 2009; Ntaios
et al., 2009; Ciaccio and Bellia, 2010; Lim et al., 2010). In summary,
the COMT gene may be a candidate gene for the genetic liability poss-
ibly shared between preeclampsia and cardiovascular disease. Altered
COMT enzyme activity and 2-ME production is likely to be of great
importance in the development of both preeclampsia and cardiovascu-
lar diseases (Dubey and Jackson, 2009).
Based on research showing that due to strong pair wise LD
between rs6269–rs4818 and rs4633–rs4680, two of these central
four SNPs were considered to be sufﬁcient to tag the variation in a
Norwegian population (Halleland et al., 2009). In the present study,
the two SNPs (rs6269 and rs4680) were selected in order to rep-
resent three major haplotypes and a fourth less frequent haplotype
(Fig. 1) in the central region of COMT. However, we do acknowledge
that the multiple SNPs within the COMT gene give rise to a multitude
of possible haplotype combinations, where minor differences between
haplotypes may have profound effects on the COMT activity. To
further investigate the role of genetic variation affecting COMT
activity, one should extend the haplotype analysis to include the
entire COMT gene. Only then can the ‘true’ effect of the high, inter-
mediate and low activity haplotypes examined in the present study
be controlled for. This can be done by looking at how these haplo-
types are combined with the different haplotypes of ﬂanking haplo-
blocks. However, this will require very large study samples in order
to account for the multitude of possible diplotype combinations
(Andersen and Skorpen, 2009).
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ary structure (Diatchenko et al., 2005; Nackley et al., 2006). The low
COMT activity haplotype has been suggested to have notable func-
tional consequences due to an RNA folding structure substantially
deviating from the structure of the most frequent and older high
COMT activity haplotype (Nackley et al., 2006). Reduced enzymatic
activity corresponding to the low COMT activity haplotype has been
shown to be paralleled by reduced protein levels (Nackley et al.,
2006). Differences in the local secondary structure of mRNA are
likely to result in differences in protein translation efﬁciency
(Nackley et al., 2006). The observation that the minor allele of an
SNP (rs2097603) located in the promoter region of the membrane
bound form of COMT producing a 1.5-fold reduction in lymphocyte
COMT activity independent of the Val158Met allele supports this
hypothesis (Chen et al., 2004). Another study found that a haplotype
consisting of two non-coding SNPs (rs737865 in intron 1 and
rs165599 in the 3′ untranslated region) reduced expression of
COMT mRNA (Bray et al., 2003). The effect of the minor allele of
three minor SNPs (rs6267, rs74062 and rs8192488) linked to the
low COMT activity haplotype was recently studied. However, none
of these minor SNPs signiﬁcantly altered COMT RNA abundance,
protein expression or enzymatic activity (Nackley et al., 2009). A hap-
lotype consisting of the minor alleles of rs737865 and rs4818 in the
low activity haplotype are associated with increased thermal threshold
variance, implicating a role for additional unobserved functional poly-
morphisms in the gene (Shibata et al., 2009). Furthermore, it has
been suggested that effects of the intermediate and low activity haplo-
types might be modiﬁed by epistatic interactions (i) occurring at gene
loci nearby COMT or (ii) with mutations located in convergent mol-
ecular pathways (Nackley et al., 2009). Thorough re-sequencing of
the COMT gene and impinging regions in order to identify additional
SNPs would be of great interest. In addition, seven different mRNA
splice variants exist for the COMT gene, which potentially exacerbates
the complexity of COMT in biological mechanisms (Tunbridge et al.,
2007). Finally, in future studies it would also be of great interest to
look at the fetal contribution since placental COMT is likely to be
of importance.
Our total preeclampsia cohort was selected based on registry data
and is therefore likely to represent a broad continuum of pathogen-
esis, ranging from mild preeclampsia to severe preeclampsia with
both maternal and fetal complications. In the present study, we
demonstrated signiﬁcant association between the low activity COMT
haplotype and recurrent preeclampsia, but not non-recurrent pree-
clampsia. A possible explanation for this might be that the recurrent
preeclampsia group represents an ‘end tail’ or extreme subgroup of
the continuum, with a greater power to detect genetic variation
underlying disease development (Terwilliger and Goring, 2000). Our
result may suggest that this group, although smaller, has a greater
power to detect genetic variation underlying disease development.
Follow up studies in larger collections are warranted.
The aim of this study was to examine if COMT activity haplotypes
observed in the Norwegian population were associated with pree-
clampsia. The two SNPs genotyped represent the four possible haplo-
types that were independently tested. Since the outcomes of the tests
performed for the four haplotypes are expected to be highly depen-
dent, we have chosen not to include a conservative Bonferroni correc-
tion (dividing the P-value threshold with the number of tests
performed, 0.05/4 ¼ 0.0125). Using a conservative Bonferroni cor-
rection to adjust the P-value threshold due to testing two preeclamp-
sia subgroups to 0.025 (0.05/2), the P-value for association between
the recurrent preeclampsia group and the low activity haploype would
still yield a signiﬁcant result (P ¼ 0.018). Although the evidence pre-
sented is not strong, our observation that a low COMT activity haplo-
type is associated with recurrent preeclampsia is consistent with other
studies reporting low COMT protein expression (Kanasaki and Kalluri,
2009) and enzyme activity (Barnea et al., 1988) in preeclampsia. Larger
studies are needed to further elucidate the hypothesis that genetic
variation within the COMT gene could be an explanation for disruption
of COMT and 2-ME homeostasis in preeclamptic women.
In conclusion, the available evidence makes COMT a likely and inter-
esting candidate gene for preeclampsia development. The present
study demonstrates that a low COMT activity haplotype contributes
to the genetic liability of recurrent preeclampsia in our Norwegian
HUNT2 cohort. Nonetheless, further genetic and functional studies
are needed to validate our ﬁnding and clarify the role of the COMT
enzyme in preeclampsia pathogenesis. Studies examining the
expression and activity of the COMT enzyme throughout pregnancy
are warranted.
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